دورية أكاديمية
Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
| العنوان: | Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG. |
|---|---|
| المؤلفون: | Soenderstrup IMH; a Department of Surgical Pathology Region Zealand , Zealand University Hospital , Slagelse , Denmark., Laenkholm AV; a Department of Surgical Pathology Region Zealand , Zealand University Hospital , Slagelse , Denmark., Jensen MB; b Danish Breast Cancer Group , Rigshospitalet, Copenhagen University Hospital , Copenhagen , Denmark., Eriksen JO; a Department of Surgical Pathology Region Zealand , Zealand University Hospital , Slagelse , Denmark., Gerdes AM; c Department of Clinical Genetics , Rigshospitalet, Copenhagen University Hospital , Copenhagen , Denmark., Hansen TVO; d Center for Genomic Medicine , Rigshospitalet Copenhagen University Hospital , Copenhagen , Denmark., Kruse TA; e Department of Clinical Genetics , Odense University Hospital , Odense , Denmark., Larsen MJ; e Department of Clinical Genetics , Odense University Hospital , Odense , Denmark., Pedersen IS; f Section of Molecular Diagnostics , Clinical Biochemistry, Aalborg University Hospital , Aalborg , Denmark., Rossing M; d Center for Genomic Medicine , Rigshospitalet Copenhagen University Hospital , Copenhagen , Denmark., Thomassen M; e Department of Clinical Genetics , Odense University Hospital , Odense , Denmark., Ejlertsen B; a Department of Surgical Pathology Region Zealand , Zealand University Hospital , Slagelse , Denmark.; g Department of Oncology , Rigshospitalet, Copenhagen University Hospital , Copenhagen , Denmark. |
| المصدر: | Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2018 Jan; Vol. 57 (1), pp. 95-101. Date of Electronic Publication: 2017 Nov 22. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Medical Journals Sweden AB Country of Publication: England NLM ID: 8709065 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1651-226X (Electronic) Linking ISSN: 0284186X NLM ISO Abbreviation: Acta Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2024- : [Uppsala, Sweden] : Medical Journals Sweden AB Original Publication: Stockholm, Sweden : Acta Oncologica, [1987- |
| مواضيع طبية MeSH: | Mutation*, BRCA1 Protein/*genetics , BRCA2 Protein/*genetics , Breast Neoplasms/*genetics , Breast Neoplasms/*mortality, Adolescent ; Adult ; Aged ; Breast Neoplasms/pathology ; Breast Neoplasms/therapy ; Chemotherapy, Adjuvant ; Denmark/epidemiology ; Disease-Free Survival ; Female ; Genetic Predisposition to Disease ; Heterozygote ; Humans ; Mastectomy ; Middle Aged ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Registries ; Young Adult |
| مستخلص: | Background: In breast cancer (BC) patients a cancer predisposing BRCA1/2 mutation is associated with adverse tumor characteristics, risk assessment and treatment allocation. We aimed to estimate overall- (OS) and disease-free survival (DFS) according to tumor characteristics and treatment among women who within two years of definitive surgery for primary BC were shown to carry a mutation in BRCA1/2 . Material and Methods: From the clinical database of the Danish Breast Cancer Group we included 141 BRCA1 and 96 BRCA2 BC patients. Estrogen receptor and HER2 status were centrally reviewed on paraffin-embedded tumor tissue. Information on risk reducing surgery was obtained from the Danish Pathology and Patient Registries and included as time-dependent variables in Cox proportional hazard models. Results: Ten-year OS and DFS for BRCA1 BC patients were 78% (95% CI 69-85) and 74% (95% CI 64-81). Ten-year OS and DFS for BRCA2 BC were 88% (95% CI 78-94) and 84% (95% CI 74-91). BRCA1 BC patients as compared to BRCA2 BC patients had a higher risk of BC relapse or non-breast cancer within ten years of follow-up, independent of ER status (adjusted HR 2.78 95% CI 1.28-6.05, p = .01), but BRCA mutation was not associated with OS (adjusted HR 1.98, 95% CI 0.87-4.52, p = .10). In multivariate analysis, including both BRCA1 and BRCA2 carriers, no chemotherapy was associated with a higher risk of death (adjusted OS HR 3.58, 95% CI 1.29-9.97, p = .01) and risk reducing contralateral mastectomy (RRCM) was associated with a significantly reduced risk of death (adjusted OS HR 0.42, 95% CI =0.21-0.84, p = .01). Conclusion: Difference in OS between BRCA1 and BRCA2 BC patients could be ascribed to tumor-biology. BRCA1 BC patients may have a shorter ten-year DFS than BRCA2 BC patients. Chemotherapy and risk reducing contralateral mastectomy reduce mortality for both BRCA1 and BRCA2 BC patients. |
| المشرفين على المادة: | 0 (BRCA1 Protein) 0 (BRCA1 protein, human) 0 (BRCA2 Protein) 0 (BRCA2 protein, human) |
| تواريخ الأحداث: | Date Created: 20171123 Date Completed: 20180201 Latest Revision: 20180201 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1080/0284186X.2017.1398415 |
| PMID: | 29164974 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1651-226X |
|---|---|
| DOI: | 10.1080/0284186X.2017.1398415 |